COO (coopercos.com) Market Value to Book Value Ratio

CooperVision (COO) - corporate logo

The current market value to book value ratio helps assess the earnings stability of The Cooper Companies (COO) within the lenses and women's health segments. The value 1.36 reflects the metric's balance, confirming the efficiency of automated sterile production lines. This chart also highlights the success of expansion through the acquisition of surgical assets, which are funded by the core business.

COO - CooperSurgical Market-to-Book Ratio over the range 07/04/2022 - 10/28/2026
Manufactured products of The Cooper Companies, Inc.

The Cooper Companies (COO) high expenditures on the development of biocompatible materials and pediatric ophthalmology create a significant gap between the value of physical assets and market expectations. This market-to-book ratio compares the company's current capitalization with its net assets, allowing investors to differentiate the business's intrinsic value from speculative noise to determine entry points.

Competitor analysis

Boston Scientific - Market Value to Book Value Ratio|EW (edwards.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio ResMed RMD|Market Capitalization to Net Assets Insulet Corp|Zimmer Biomet Holdings, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Align Corp (ALGN)|Globus Medical, Inc. - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio TransMedics Organ Care System TMDX|Market Capitalization to Book Value Ratio ATEC (Alphatec)|AORT - Market Capitalization to Book Value|ENOV: Market Capitalization to Book Value Ratio|IART (Integra LifeSciences Inc.) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Establishment Labs|Market Value to Book Value Ratio betabionics.com|IRMD (IRADIMED) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Embecta Corp EMBC|Tandem Diabetes (TNDM) - Market Cap to Net Assets Ratio|Market Capitalization to Net Assets Axogen Surgical AXGN|SIBN (SI-BONE, Inc.) - Market Capitalization to Book Value Ratio|OFIX - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Bioventus|Capitalization to Book Value Ratio OrthoPediatrics|TMCI - Market Cap to Net Assets Ratio|Market Value to Book Value SRTA|Market Value to Book Value Ratio CARL (Carlsmed Inc)|Market Cap to Net Assets Ratio rxsight.com (RXST)|CLPT: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Stereotaxis Inc STXS|NeuroStar (STIM) - Market Capitalization to Book Value Ratio|SGHT - Capitalization to Book Value Ratio|Orchestra BioMed - Market Capitalization to Book Value Ratio|Anika Therapeutics, Inc. (ANIK) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio NSPR|Market Cap to Net Assets Ratio Jin Medical International Ltd|Market Capitalization to Book Value Ratio VANI|Market Capitalization to Book Value Ratio XTNT (xtantmedical.com)|Market Value to Book Value Ratio NeuroOne Medical Technologies NMTC|MODD - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Myomo (MYO)|COCH - Market Value to Book Value|Market Capitalization to Book Value Ratio VVOS|NVNO (enVVeno Corp) - Market-to-Book Ratio|Sintx Technologies Inc - Market Value to Book Value Ratio|Market Value to Equity Ratio tenonmed.com (TNON)|Market Cap to Net Assets Ratio LFWD|Market Capitalization to Book Value Ratio autonomix.com (AMIX)|Market Capitalization to Book Value Ratio IVF|Bone Biologics Inc - Market Capitalization to Book Value|Market Value to Book Value Ratio Axonics, Inc.|BIOL: Market Capitalization to Net Assets|DYNT (dynatronics.com) - Market Value to Book Value Ratio|Paragon 28 (FNA) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio INVO (INVO Bioscience Inc.)